We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
Turnover
16.03%
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+13.69%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$53.1B
AUM Growth
+$6.76B
(+15%)
Cap. Flow
+$2.33B
Cap. Flow
% of AUM
4.39%
Top 10 Holdings %
Top 10 Hldgs %
14.65%
Holding
2,220
New
169
Increased
729
Reduced
1,033
Closed
165
Avg Time Held
5.4
years
Top 10 Avg Time Held
1.7
years
Top 20 Avg Time Held
2.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zscaler
ZS
|
+$222M |
| 2 |
Palantir
PLTR
|
+$221M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$213M |
| 4 |
FirstEnergy
FE
|
+$189M |
| 5 |
Broadcom
AVGO
|
+$174M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$383M |
| 2 |
Philip Morris
PM
|
+$280M |
| 3 |
Entergy
ETR
|
+$207M |
| 4 |
Paychex
PAYX
|
+$206M |
| 5 |
Gilead Sciences
GILD
|
+$201M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.81% |
| 2 | Healthcare | 14.57% |
| 3 | Financials | 13.43% |
| 4 | Industrials | 10.29% |
| 5 | Consumer Discretionary | 9.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1001
Rocket Pharmaceuticals
RCKT
$259M
| $1.53M | ﹤0.01% |
624,303
+209,806
| +51% | +$1.06M |
2025 Q1
1 quarter
|
|
1002
Tenet Healthcare
THC
$22.2B
| $1.53M | ﹤0.01% |
8,671
-21,215
| -71% | -$3.19M |
2013 Q2
48 quarters
|
|
1003
Synaptics
SYNA
$4.67B
| $1.51M | ﹤0.01% |
23,352
+1,939
| +9% | +$114K |
2015 Q3
39 quarters
|
|
1004
Federated Hermes MDT Large Cap Growth ETF
FLCG
$642M
| $1.51M | ﹤0.01% |
50,004
-50,000
| -50% | -$1.36M |
2024 Q3
3 quarters
|
|
1005
EXL Service
EXLS
$5.93B
| $1.51M | ﹤0.01% |
34,441
-365
| -1% | -$16.7K |
2018 Q4
26 quarters
|
|
1006
PROG Holdings
PRG
$1.24B
| $1.5M | ﹤0.01% |
51,263
-7,200
| -12% | -$200K |
2020 Q4
18 quarters
|
|
1007
Carlisle Companies
CSL
$13.3B
| $1.5M | ﹤0.01% |
4,029
-370
| -8% | -$137K |
2013 Q2
48 quarters
|
|
1008
Saic
SAIC
$5.59B
| $1.5M | ﹤0.01% |
13,328
-3,558
| -21% | -$405K |
2013 Q4
46 quarters
|
|
1009
Brink's
BCO
$4.3B
| $1.49M | ﹤0.01% |
16,676
-6,007
| -26% | -$523K |
2017 Q2
32 quarters
|
|
1010
Vitamin Cottage Natural Grocers
NGVC
$705M
| $1.49M | ﹤0.01% |
37,929
+21,062
| +125% | +$975K |
2023 Q2
8 quarters
|
|
1011
W.P. Carey
WPC
$14.7B
| $1.48M | ﹤0.01% |
23,709
-2,643
| -10% | -$163K |
2023 Q4
6 quarters
|
|
1012
First Bancorp
FBNC
$2.5B
| $1.47M | ﹤0.01% |
33,397
+10,909
| +49% | +$442K |
2013 Q4
46 quarters
|
|
1013
Pediatrix Medical
MD
$2.26B
| $1.47M | ﹤0.01% |
102,452
-61,051
| -37% | -$837K |
2022 Q2
12 quarters
|
|
1014
RenaissanceRe
RNR
$14.3B
| $1.47M | ﹤0.01% |
6,043
+10
| +0.2% | +$2.42K |
2013 Q2
48 quarters
|
|
1015
NMI Holdings
NMIH
$3.02B
| $1.47M | ﹤0.01% |
34,765
-1,015
| -3% | -$38.1K |
2023 Q3
7 quarters
|
|
1016
Veracyte
VCYT
$3.57B
| $1.46M | ﹤0.01% |
54,167
-40,256
| -43% | -$1.17M |
2024 Q1
5 quarters
|
|
1017
iShares JPMorgan EM Local Currency Bond ETF
LEMB
$781M
| $1.45M | ﹤0.01% |
+35,988
| New | +$1.4M |
2025 Q2
0 quarters
|
|
1018
Somnigroup International
SGI
$14.9B
| $1.45M | ﹤0.01% |
21,311
+3,204
| +18% | +$202K |
2013 Q2
48 quarters
|
|
1019
Agilent Technologies
A
$49.5B
| $1.45M | ﹤0.01% |
12,281
-21,945
| -64% | -$2.43M |
2013 Q2
48 quarters
|
|
1020
Columbia Banking Systems
COLB
$8.1B
| $1.45M | ﹤0.01% |
61,944
-75,842
| -55% | -$1.76M |
2023 Q1
9 quarters
|
|
1021
Hurco Companies Inc
HURC
$135M
| $1.45M | ﹤0.01% |
76,531
+618
| +0.8% | +$9.32K |
2017 Q2
32 quarters
|
|
1022
CDW
CDW
$19.3B
| $1.44M | ﹤0.01% |
8,076
+3,004
| +59% | +$510K |
2013 Q4
46 quarters
|
|
1023
Red Rock Resorts
RRR
$2.98B
| $1.43M | ﹤0.01% |
27,535
-2,975
| -10% | -$136K |
2019 Q2
24 quarters
|
|
1024
Peapack-Gladstone Financial
PGC
$770M
| $1.43M | ﹤0.01% |
50,594
+1,676
| +3% | +$46K |
2016 Q2
36 quarters
|
|
1025
Entegris
ENTG
$22.4B
| $1.42M | ﹤0.01% |
17,661
-153,253
| -90% | -$11.6M |
2021 Q4
14 quarters
|
|
Similar funds
Federated Hermes's Q2 2025 Portfolio in Review
As of Q2 2025, Federated Hermes held 2,220 positions worth $53.1B, up 15% from $46.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes deployed $2.33B of net new capital in Q2 2025, opening 169 new positions and adding to 729 existing holdings. Its largest new stake was Genuine Parts: 882,160 shares worth $107M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $383M trimmed.
- Federated Hermes's largest Q2 2025 buy was Genuine Parts: 882,160 shares worth $107M.
- Federated Hermes added most to Zscaler in Q2 2025, an estimated $222M increase.
- Federated Hermes's biggest Q2 2025 reduction was Bristol-Myers Squibb, cutting an estimated $383M.
- Federated Hermes fully exited Regulus Therapeutics in Q2 2025, selling an estimated $39.2M.
- Federated Hermes's ten largest holdings make up 15% of its $53.1B portfolio in Q2 2025.
- Federated Hermes opened 169 new positions and closed 165 in Q2 2025.
- Federated Hermes's portfolio value rose 15% quarter-over-quarter to $53.1B.
Based on Federated Hermes's 13F filing for Q2 2025, filed 13 Aug 2025.